Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Vicore Pharma, Webcast, 2024

By Inderes5/22/2024, 2:00 PM
Vicore Pharma Holding

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Megan Richards
00:00 - 00:33

Everyone, and thank you for joining the Vicore Pharma webinar, where we will present and analyze the final results from the Phase 2a AIR trial investigating Buloxibutid over 36 weeks in idiopathic pulmonary fibrosis. My name is Megan Richards and I'm the VP of Investor Relations, Communications, and Portfolio Strategy at Vicore Pharma, and I will be moderating the session today. Our speakers today will present key insights from the data for about 40 minutes, and then we will open up the discussion for Q&A. To kick things off, I will turn the conversation over to Vicore Pharma CEO Ahmed Mousa.

Ahmed Mousa
00:35 - 11:07

Thank you, Megan, and thank you everyone for joining. Good morning. Good afternoon, I'm Ahmed Mousa. I'm the CEO of Vicore Pharma since September of 2023. Uh, I'm really excited to have joined the company after the highly promising interim results of this Phase 2a study of Buloxibutid were revealed, especially as I previously worked in IPF and felt that these data reflect disease-modifying potential in an area of such high unmet need. You know, my enthusiasm for the approach also stemmed from my time in the lab, where I saw firsthand the ability of angiotensin II pathway modulation to resolve fibrosis in other disease contexts. Now, with me here today, presenting Bertil Lindmark, our chief medical officer, he is a highly experienced drug developer, was previously the vice president of clinical development for respiratory at AstraZeneca, leading the approval of large respiratory franchise drugs Symbicort and Pulmicort. He was the head of R&D at Almirall, bringing a COPD medication to the market, and he's been the chief medical officer of a number of biopharmaceutical companies, leading clinical development programs, including large late-stage IPF programs as well. And of course, last but not least, we have Professor Toby Maher, who really needs no introduction. He's amongst the world's leading clinicians in the development of therapies for pulmonary fibrosis and currently the director of the ILD center and a professor at the University of Southern California. On the next slide, we can quickly look at the agenda. And so, first, I'll talk a little bit about the rationale for Buloxibutid in IPF, why we think this approach is the right one. Uh, and next, Professor Maher will review the final Phase 2a data as it was presented at ATS. And after that, Bertil will give us some deeper context on the dataset and also place it in the broader therapeutic landscape. And after that, I will make some connections between what we've seen preclinically and clinically with respect to the mechanism. And also talk about the Phase 2b ASPIRE trial that we're excited to kick off in the coming months as well. And finally, we'll, of course, do the Q&A as Megan mentioned. Uh, so first and foremost, then you know why Buloxibutid for IPF. You know, we all know that IPF is a tough disease of progressive fibrosis. It essentially chokes off patients' ability to breathe. With only 2 to 5 years of survival. You know, from diagnosis with the current therapies. And there have also been a number of therapies that have, you know, not worked in recent years. So then why Angiotensin II type 2 receptor agonist? Um, you know, for IPF. And if we look at this kind of schematic of the mechanism, what Buloxibutid is doing is selectively agonizing on. Right, and orange, this AT2 receptor, which is an endogenous tissue repair system that sits within this broader, uh, angiotensin II pathway. We believe that agonizing this upstream mechanism of action provides broad anti-fibrotic and tissue repair capabilities. And it's a really effective approach for a heterogeneous disease like IPF, as opposed to downstream antagonistic approaches that might block collagen deposition. And just to kind of orient you to this Angiotensin II pathway, when you look at the Angiotensin II peptide, it signals on both the AT1 and the AT2 receptors. And these receptors act as opposing forces in the body. The AT1 pathway is a hypertensive, pro-fibrotic, pro-inflammatory pathway. And that's actually an entirely suitable response to certain injuries, infections, or insults to ensure that you maintain good blood pressure. So it's very conservative. You see it in most species, and it's quite important; because of its importance, the AT1 pathway or AT1 receptor is broadly and constitutively expressed across tissues. And so for that reason, when there's Angiotensin II peptide release, the net effect is typically this AT1 phenotype: hypertension, inflammation, fibrosis leading to the development of ACE inhibitors and angiotensin receptor blockers. What is interesting about this AT2 receptor is that it's much more selectively expressed both in tissues and over time. So in most tissues, you don't find the AT2 receptor basically expressed. Rather, it's upregulated after there's an extended high hypertensive, fibrotic, or inflammatory process. And then it becomes upregulated so that it can resolve those processes over time. Interestingly though, one of the few tissues where you'll find basal and constitutive expression of the AT2 receptor is the lung. And we believe that's because you're always breathing in some external particles that might drive some of these fibrotic or inflammatory processes. It's great to have a built-in system there to always be resolving that. And for whatever reason, it's there. And so, our main thesis is to essentially supercharge the endogenous tissue repair system against the tough disease that is IPF. And the other thing that's very interesting is actually the primary cell type in which you'll find this AT2 receptor expressed are these precursor alveolar epithelial type two cells. And so, if we look at the next slide, we can see why these cells are important for the healthy function of the alveolus, a critical compartment of the lung. You know, for breathing. And these really exist at the distal lung and are critical for gas exchange. And so when you look at the type 2 cells, you know, first and foremost, do they actually differentiate into the type 1 gas exchange cells, which are the main cell type of the alveolus. So that's a very important function for them. A second key function that we highlight for the healthy function of the alveoli is the production of surfactant proteins. Surfactant proteins involved in the innate immune response are also crucial in addressing the surface tension associated with water. So, in the absence of these surfactant proteins, there's the surface tension of water, and the alveoli would drive the collapse of this compartment. And so that's quite a critical function for this, for this cell type as well. So maybe if we push forward, then we say, 'Okay, well, what happens in the? It is the state of IPF that affects the alveoli. And what happens to the state of type two alveolar epithelial cells in the diseased state of IPF? And so you see here on the left, the injury to the lung that drives this fibrotic process. It doesn't spare the type two cells. So they become dysfunctional. They undergo apoptosis. So there's a reduction in that population of cells. And that injury then of course cuts off the ability of this cell type to produce surfactant protein, leading to what's known as pre-fibrotic alveolar collapse due to loss of surfactant production. And what that essentially means is even before the fibrotic buildup, you know, inhibits the gas exchange you actually have, the alveoli unable to, you know, participate in that process because it no longer has its integrity. And so that's a critical function. In addition to that, of course, the dysfunction of these type two cells is going to lead to less replenishment of the type one gas exchange cells, which of course are quite important. And then further than that, you know, when you have the injury to the type two epithelial cells, it drives them to release this fibrotic cytokine in response to the injury, this TGFβ1. And this is widely recognized to be a master regulator of fibrosis. And you know that TGFβ1 then drives what's called this epithelial to mesenchymal transition, where these type two epithelial cells, which should be differentiating more into the type one cells, are now differentiating into fibroblasts. And then ultimately myofibroblasts, which are the kind of key drivers of the collagen deposition and buildup of fibrosis in the lung. Interstitium. And then last but not least, TGFβ1 is involved in the dysregulation of the matrix metalloproteinases, and in particular there are a set of matrix metalloproteinases known to be collagenases that can break up the collagen, and those classes are downregulated in the disease state that is IPF. So with a lot going on that drives this fibrotic process, on the right-hand side, we see what Buloxibutid is postulated to do to alleviate this. And first and foremost, we're agonizing this Angiotensin II type 2 receptor on these type two epithelial cells to stabilize them and basically allow them to continue to survive, to continue to produce surfactant, and to continue to be available to differentiate into type one gas exchange cells. So that's going to be the first piece of the puzzle. And then the second piece of the puzzle is an inhibition of TGFβ1. So agonist of the type two receptor will downregulate expression of TGFβ1. It will downregulate expression of TGF beta receptor that it signals on. And also we've shown in vivo it will downregulate the signaling through the key pathways by which TGFβ1 drives its fibrotic activity. So a significant impact on that particular cytokine, which we think is important and that ultimately will inhibit that epithelial to mesenchymal transition that we talked about. So stop the type two precursor cells from differentiating into fibroblasts. Then ultimately myofibroblasts. And then last but not least we have then an upregulation also of the Chinese type MMP through this matrix, so that we have the enzymes available to break down the fibrosis that's already built up. On the next slide. You know, when we put this all together, this is what really underscores our excitement. We think we have the right mechanism with an upstream, kind of broad approach to drive an endogenous tissue repair system. We have this really nice, phase 2a signal that Toby Maher and Bertil Lindmark will talk more about. And then we have the right next experiment with a robust phase 2b design to really demonstrate in a larger study and a placebo-controlled study, the effect and the safety of this molecule for IPF. Uh, so from here, I'll turn it over to Professor Maher, who will review the Phase 2a AIR trial data as we did at ATS.

Prof. Toby Maher
11:09 - 25:29

Uh, great. Thank you. Um, so, yeah, it's a pleasure to be here today to talk everyone through the results of this study. Um, if we can move to the next slide. Um, so people may well have seen the interim version of this data before. This is now the full and final data set. Um, and just to remind everybody of the trial design, uh, this was an open label, uh, multicenter, uh, international phase 2 trial of, uh, Buloxibutid at a dose of 100mg twice daily, given for up to 36 weeks in treatment-naive patients. Um, and there are a few important parts of the study design just to focus on. Um, so first of all. As is the standard with late phase clinical trials in idiopathic pulmonary fibrosis. All patients had to have central reading of their CT scan to confirm that they had idiopathic pulmonary fibrosis before they could enter into the trial. Um, and that's been an important sense check in IPF trials to make sure that we are actually studying the population of patients, uh, that we want with, um, ultimately progressive fibrotic lung disease. Um, as you can then see from the trial schematic, uh, patients went through screening, uh, and once enrolled into the study, uh, underwent regular study visits. The primary endpoint of the trial was safety and tolerability. Um, the efficacy endpoint of forced vital capacity, uh, was measured as a secondary endpoint. And as we will touch on, uh, there were exploratory biomarker endpoints, um, along with the forced vital capacity. Again, there are a few things to focus on there. Uh, so although this was an open label study, the spirometry was again performed essentially to Phase 3 standards, which is to say that there was, uh, a standardized spirometry device provided to each center and that there was, um, central overreading, uh, of all the spirometry results. Again, that's an important step, uh, in the quality control process to ensure that the spirometry that is obtained by sites, uh, has been well performed and is accurate and interpretable. And then finally, if we look at the study schematic, you will see that there was a plan, um, for frequent study visits, um, in 2019, when the study was being put together, this seemed like a great idea. Uh, the goal really being to ensure that by collecting frequent FVC measures, we were going to have a very clear, uh, impression of individual disease trajectories. Uh, of course, with the onset of Covid in 2020. Um, having quite so many touch points, uh, with, uh, the clinic, um, actually became something of a weakness for the study. Uh, and as you'll see, this led to a number of dropouts with patients, uh, during 2020 and early 2021, uh, often being very scared about coming up to healthcare facilities, uh, because of concerns about Covid. And so that's, that's just something to keep in mind. Uh, as we said, patients were treatment naive. Uh, and there were two specific visits where investigators were asked to consider whether patients should be exiting the study onto open label or onto standard of care therapy. Uh, and then patients were ultimately followed up to week 36 on treatment. Um, so if we can move to the next slide. Um, so this is the study disposition. Um, 138 patients were screened, 86 of whom failed screening. Uh, that may seem like a high screen failure rate, but it's comparable to other late phase studies in IPF. And a lot of that screen failure is accounted for, um, by the central reading of the CT scan. So in some ways, it's important that there was a significant screen failure rate because it tells us that patients were appropriately not being included in the study, uh, if they didn't have the CT appearances of idiopathic pulmonary fibrosis. So ultimately, 52 patients were enrolled. And then, as I've alluded to, uh, there were a reasonable number of dropouts. So 24 patients didn't make it to week 36. And the vast majority of those dropped out during the Covid pandemic. Uh, as we said, because of concerns about attending healthcare facilities during the pandemic, uh, the minority dropped out because of, um, drug-related reasons. And we'll come on to that on the next slide. Uh, so 28 completed the week 36 visit. And then for our safety analysis data set, we have 52 patients, uh, and for the efficacy analysis set, we have 50 patients. If I can have the next slide. Um, these are the baseline demographics of the patients. Um, now, uh, in general, this looks very similar to what we see in comparable late phase IPF trials. Uh, so we have predominantly men, uh, in their mid to late 60s. Um, the racial, um, makeup reflects the countries in which the study was conducted. Um, the time from diagnosis, uh, of one year, again reflects the fact that these were treatment-naive patients. So these were patients, um, very early after diagnosis, who had either chosen not to go on anti-fibrotic drugs, uh, or, um, did not have access to reimbursed therapy. And then if we look at disease severity, again this is very similar to what we see in late phase IPF trials with at least moderate disease severity and an FVC of 75% predicted. Um, and then just the final bit to point out is that when we look at the CT pattern and when it is centrally read, um, we can divide patients up into these sort of typical and probable groups. Uh, and so, uh, just over a third of patients had what we call a typical UIP appearance, uh, while two-thirds had a probable UIP appearance. Again, this is comparable with um, late phase studies that have been conducted in this disease area. So next slide. Um, so, as I said, safety and tolerability were the primary endpoints of the trial. Um, and if we start first on the left hand side, uh, with the safety, um, we can see that there were not any serious or severe, uh, treatment-emergent adverse events that were ascribed to the drug itself. Um, there were, uh, three AEs that, um, resulted from or that were ascribed to the drug and resulted in withdrawal from the trial. Um, uh, and as you can see, there were no deaths ascribed to the drug. Um, if we look on the right hand side, um, the main side effect that was seen and that can be ascribed to the drug is hair loss. Uh, this was recognized in the phase one trials, and this, uh, in phase one appeared to be a dose-dependent side effect. Um, at very high doses, um, a few patients lost all body hair, um, at the dose used in this trial, 100mg twice daily. The hair loss that was reported was described as mild to moderate at worst. And only one patient discontinued treatment due to this hair loss. It might be noted that the current drugs in this space, which cause intended puffiness, do not have significant gastrointestinal side effects, making it often difficult to combine treatments that have additional GI side effects with diphenhydramine. It's important to note that Buloxibutid didn't have any appreciable GI tolerability issues. So if we can move on to the next slide. And so this is the FVC data. I think this is the very exciting part of the trial. Now, of course, this was an open label study. And so we did not have a placebo group. The dotted line on this graph represents a hypothetical line describing the trajectory that we would expect a standard IPF population of patients would follow. And this is really based on our 20 years' experience of running clinical trials in this disease area. We know from that experience that the average IPF placebo group loses somewhere between 100 to 240ml of FVC per 12 months. So we've just sort of put the dotted line on there as an indicator of what might have been expected from a placebo group. The green line is what was observed in the patients being treated with Buloxibutid. So, each timepoint represents the observed mean for that timepoint. And you'll see there's a little number under each green circle that reflects the number of patients who provided measurements at each of those timepoints. As we've said, there was an early dropout rate, which was primarily ascribed to COVID-19. So we do see some attrition in numbers over time. But the startling thing about this line is that it's going upwards, suggesting an improvement in lung function over the 36 weeks of the study. And for those of you on the line who have looked at other IPF clinical trials, this is not something that we generally see with the approved therapies. We see a slowing of disease decline so that the treatment line has tended to mirror the placebo line, albeit with a more shallow level of deterioration over time. So to be seeing a set of results where we're seeing an upward inflection in the curve is very exciting from my perspective. Clearly, we have to caveat this with the fact that it's an open label study. We do know that occasional patients with IPF who are untreated do show some mild improvements in lung function over time. But taking a Bayesian approach to interpreting this data, the chances of accidentally enrolling 28 patients who show a persistent improvement in FVC over 36 weeks is minuscule. I find this data to be incredibly tantalizing in terms of suggesting an effective treatment. If we can move forward. And then Megan Richards have started trying to dig into other data and look at some of the plasma biomarker responses. And we put here two potentially important biomarkers. So on the left-hand side we have TGFβ1. Um, Ahmed has already described TGF-beta as the master regulator in idiopathic pulmonary fibrosis. And certainly, it's a very important fibrotic cytokine. So seeing a reduction in TGF-beta levels would suggest an important effect on fibrotic pathways. On the right hand side, what we see is an increase in MMP-13. MMP-13 is responsible for the degradation of collagen and extracellular matrix. And so an increase in plasma MMP-13 would suggest increasing collagen activity with exposure to treatment. And again, that's something that would be considered a good thing to happen in the treatment of IPF. So if I can have the next slide. Having talked you through all the data, this is just the summary. Ahmed gave you the rationale for why targeting the angiotensin II receptor makes sense. Buloxibutid is a novel drug targeting this mechanism. We've shown you the safety profile, which I believe is very good. There is that one tolerability issue of hair loss, which has been mild to moderate. And I think in a population of predominantly older men, is not something that has caused concerns with patients enrolled in the study. And finally, I've shown you the lung function data, which, as I've said, has to be caveated by the fact that this is an open-label study. But really, for me, it is incredibly tantalizing given how the treatment curve differs so startlingly from what we've seen in other drug trials in this disease space. So I will stop there, and I will hand over now to Bertil for the remainder of the session.

Bertil Lindmark
25:30 - 33:34

Anyway, I want to give some extra context to the data and do a little bit of comparison with historical data and try to set this in perspective. And it's pretty obvious if we have shown a shallower decline of FVC, then we wouldn't have engendered as much interest as we have. But actually we have for the first time shown a pretty dramatic increase in FVC. So can I have the first slide please? We took very much care to include the right patients, as Toby was saying. And when you compare here with the patients in the placebo group, they were very much alike in terms of age, gender, BMI, etc. The lung function was actually slightly worse in the AIR trial. So the patients had lost 25% of their lung function. And this is, the combination of HRCT and FVC percent predicted. I think that tells the story that these patients had really bona fide IPF and that there is a good comparison with historical data based on that. Next slide, please. Toby showed the benefit or the good side effect profile. And I think this is another sort of contrasting data set because, you know, can you achieve an increase in lung function and still be very tolerable? And you look at the side effects, they were extremely good on the GI side with a low rate of exacerbations and cough worsening, which are kind of key IPF characteristics and then sort of comparable or much better serious, severe, or fatal events non-related to Buloxibutid. So given the side effect profile and given the kind of effect opportunity that we see with Buloxibutid, we think that you could be thinking of it as a first-line therapy and you could be thinking of combining Buloxibutid with most of the currently present or upcoming therapies. So this is a good starting point, sort of a tolerable therapy with potentially good disease-modifying characteristics. Next slide, please. And as Toby was pointing out, it sort of goes in the wrong direction. But for the patients with IPF, I think it goes in the right direction. And obviously, you can prove any approved drug with, by cutting and slicing the data into really small buckets. Here we look at the different subgroups in the trial, both in terms of gender, geography, and type of IPF. We discuss the probable UIP and the typical UIP, depending on the HCT pattern or all end up north of the horizontal line showing improvement. And when we look at both the mean and the median FVC change, you can see that both are positive. And that tells you that this is not driven by singular patients or a subgroup of high responders. The dataset is internally highly consistent. So that tells you that patients had confirmed IPF, and they reacted completely differently. And it's not a single patient or a subgroup that sort of skews this data. Next slide, please. When we look at the percent predicted, you know, this is a way to link lung function to body size and the height of the patients. For example, Buloxibutid again shows both a mean and a median improvement compared to baseline. We added the untreated patients from the impulsive studies and the knitted patients just for comparison. And, we interpolated down to 36 weeks. So here again, a percentage predicted is consistent with an increase in absolute efficacy and highlights the uniqueness of the intervention. Next slide, please. And when we compare with the untreated in the same study, we outperform by 8.082%. So it's really a population shift that we accomplish with the Buloxibutid intervention. Next slide, please. Here we look at the percentage of patients with improved lung function versus baseline. And of course, as Toby mentioned, how likely is it that in a population like this, with 52 patients, you would see an accumulation of patients with vastly improved lung function? Well, if we compare with the untreated, that's about 9%. You would think of maybe five patients maximally, or perhaps ten, but it would still be much less than what we saw in the earlier trial's standard care. 25% are also not doing as well as Buloxibutid noted. And there is a sort of internal consistency in the data. There is the loss of lung function, the previous loss of lung function, indicating that these are bona fide IPF patients who actually experience an increase in lung function. Next slide, please. So in the trial we conducted a risk-benefit evaluation at week 12 and week 24, and the physicians were prompted to think about whether the benefit-risk was acceptable and whether it was indicated to start antibiotic therapy. One patient in the whole study transitioned from the study into anti-fibrotic therapy, and overall, 97% benefited. Both time points proceeded in the study, and it was felt that the benefit-risk balance was fine. So what I'm trying to say today is that we have a population that looks similar to previous populations, but with a completely different side effect profile, extremely well tolerated and with no gastrointestinal side effects worth mentioning. And really, however we cut the data, the internal consistency and the comparison with historical data outside of the trial is really sort of telling that we have potentially a drug that could be extremely well positioned, both for patients in the first line and also in combination with other therapies that might be approved in the meantime. So with that, I'll finish my talk and hand over to Ahmed. Over to you.

Ahmed Mousa
33:35 - 40:26

Yes, thank you very much, Bertil. And, you know, we have Prof. Toby Maher who talked about the clinical data, and Bertil Lindmark, who put it into a broader context. And before I talk about the Phase 2b design, I'd just like to link, you know, what we saw in the clinic with our postulated mechanism of action and even a couple of pieces of translational data that we have. On the next slide, just a reminder of what Professor Maher showed: the decrease in plasma TGFβ1 trend as well as the increase in the collagen type MMPs. But exactly what does this mean, and why are these important, and how does it link to our kind of preclinical data set, and why we think this mechanism is important. So, just on the next slide, really, you know, again, kind of reinforcing the importance of this pro-fibrotic cytokine that stimulates the extracellular matrix formation and drives the transition of type two cells to ultimately become myofibroblasts for collagen deposition. And also plays a role in the MMP imbalance associated with disease progression. So it's been very nice to see very consistently in the preclinical and translational data sets that Buloxibutid inhibits the expression of TGFβ1. And on the right-hand side, this is an ex vivo study in human IPF precision-cut lung slices. But we've generated similar data in vivo and in other models as well. In addition to the effect on the levels of TGFβ1, we also have very nice data in vivo reflecting inhibition of the signaling pathways. This map to three signaling associated with TGFβ1's pro-fibrotic drive. For us, the correlation between what we observe in the preclinical and translational data sets, the blood biomarkers, and ultimately in lung function has been very exciting. And then maybe if we move to the next slide, there's also, right, as we said, this kind of increase in collagen-type MMP-13. And there have been a number of studies that have shown that this is an important, um, an important, uh, matrix metalloproteinase for breaking up the collagen matrix. On the right hand side, you'll see a study where they knocked out MMP-13 in mice and then challenged them, leading to a greater level of fibrosis and lung damage. So, this is an MMP that is known to decrease genetic activity. Sorry to increase cloud activity and to promote resolution of lung fibrosis. And so it's been very nice to see them. The correlative plasma biomarker work is consistent with the importance of this type of matrix metalloproteinase. And this is also consistent with our translational data sets showing increases in the matrix metalloproteinases. And then the third slide, this is also the third piece of the puzzle which I think is not to be forgotten. Right. And this is the impact on type 2 alveolar epithelial cells and surfactant production. So again here, just to clarify, we're showing a small study in vitro on the left-hand side, where you co-culture the type two alveolar epithelial cells with glioma. Essentially, you're simulating the injury that occurs in the alveolus in the IPF disease state. And that will lead to apoptosis and cell death in the type two alveolar epithelial cells. And here we see that C21 or Buloxibutid, when used in a concentration-dependent manner, is able to inhibit myosin-mediated apoptosis. And what should that lead to? Right. That should lead to an increase in these surfactant proteins that can address the surface tension and prevent or mitigate pre-fibrotic alveolar collapse. And our ex vivo human IPF precision-cut lung slices data are consistent with that, with an mRNA upregulation in key surfactant proteins B and C in order to address that phenomenon. So, on the next slide, if you take this and put it all together, you know what that means is that you're tackling the fibrotic drive from two ends, right? You're reducing, hopefully, the level of fibrosis with this postulated mechanism of action through TGF-β1, inhibiting expression and signaling. But you're also impacting the fibrosis through the upregulation of the claudin type MMPs. And then, as a slightly separate category, how we see it, you know, you're also impacting the alveolar integrity and addressing pre-fibrotic alveolar collapse due to loss of surfactant production. And those are some of the reasons why we believe we have seen this exciting clinical signal and why we are excited to push forward to the Phase 2b ASPIRE trial. So, maybe on the next slide, we can do a quick overview of that. So again, this is really intended to be, you know, a robust Phase 2b trial with the regulatory endpoint in mind so that we can really demonstrate, as much as we are able to, the safety and efficacy of this molecule for IPF. So it's a randomized, double-blind, placebo-controlled study. It will include IPF patients now who are on the standard of care, and or not on the standard of care. Here, whether that be treatment-naive or treatment-intolerant, or otherwise. It'll be a 52-week period where we're measuring, as the primary endpoint, change from baseline. At 52 weeks, we will include 270 patients. And we will also include two dose levels: 100mg twice daily. The same as in the Phase 2a AIR trial, as well as a 50mg twice daily dose relative to the placebo group as well. On the next slide. We'll just put into a little bit of context what it means to enroll 270 patients based on our statistical powering. So it's been very exciting to see this improvement in lung function. Um, in the Phase 2a AIR trial. And you see that as a clinical signal of activity, certainly something that could stabilize lung function, especially something that's safe and well tolerated, would be a huge win for IPF patients, would address a really high unmet medical need, and would be also a significant commercial opportunity. And so from that perspective, we've ensured that by including 270 patients in our trial, we have the statistical power to be able to detect a stabilization of lung function out to 52 weeks under the assumption of, you know, the most mild of placebo standards of care arms that have been observed in IPF trials. So we're really trying to make sure that we power this in a conservative way for success after seeing this encouraging Phase 2a clinical signal, and then on the right, just depicting that we are going for a broad geographical footprint as we advance to Phase 2b, including significant enrollment in the United States, with 20 to 30% of this study being anticipated to enroll in the US. And then, I will hand it over to Megan for the Q&A.

Megan Richards
40:28 - 40:38

Great. Thanks, Ahmed, and thank you all for an engaging presentation. We'll now open up the conversation for questions, and we'll start with the analysts on the phone and then move on to questions in the chat.

Operator
40:44 - 41:11

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Dan, actually from Pareto Securities AB. Please go ahead.

Unknown 1
41:13 - 41:42

Thank you very much for taking my questions, and congratulations again on the great data. I have mainly questions for the Phase 2b trial. Now when are you expecting the trial to start, and how do you see your data enabling you in kind of marketing to get the patient enrollment up and fast because there's still quite some competition, as you know, with other modalities. Thank you.

Ahmed Mousa
41:44 - 42:22

Yes, that's a great question. So on the timing side, we will make the regulatory submissions to initiate the Phase 2b trial starting next month. We are, of course, compiling the final Phase 2a data set to include as part of those. We've identified the 97 clinical sites that we'd like to include in the study across 14 countries. And so we're already engaged with them. Maybe on the point of how enthusiastic investigators might be, maybe I'll turn that over to Prof. Maher and see if he has any perspective on what this data set might mean for enthusiasm amongst the clinical community as we kick off the Phase 2b as well.

Prof. Toby Maher
42:24 - 43:41

Thanks, Ahmed. Yes. I think, as was alluded to in the question, it is certainly a competitive space at the moment for clinical trials. We've got at least one Phase 3 study and a large Phase 2b study running. That said, as a disease area, we've become much more experienced at recruiting patients. And the timelines, even at Phase 3, for recruiting patients have got shorter and shorter over the last decade as more and more centers have become involved in clinical trials. And I think for Phase 2 studies, one of the keys to engaging interest is really having both a good rationale and having as much good data as possible. And I think we're in an excellent position. With the data that we've just described, we can really engage with investigators, patients, and patient support groups to drive enthusiasm for this trial. And my expectation, given the data that I presented today, is that recruitment should be as easy as it gets in a Phase 2 IPF study. Given what we can tell patients about the drug to date.

Unknown 1
43:45 - 44:34

Okay, then I have one follow-up for you, Prof. Maher. If I may, I listen to your presentations quite frequently since you present a lot of data sets from other companies as well. So I wonder how, because many of these data sets are 12 weeks based, and even in Vicore's data, we don't see much at 12 weeks. How do you compare the significance of 36-week data versus 12-week data? Also, thinking about the trajectory that the writer now has for how that bodes for the 52-week trial. And if you can share anything else that you think is really standing out here in a positive or negative way. Thank you.

Prof. Toby Maher
44:35 - 46:12

Yes, it's a good question. My general view is that 12 weeks will give us a reasonable impression of the potential efficacy of a drug. I think it's unlikely that we will miss an effective drug by running 12-week studies. And if you think back to the data I showed today, um, you know, at 12 weeks, there was stabilization of FVC with Buloxibutid. So, um, that in itself, you know, would have been considered quite exciting in comparison to some other studies. You know, I think clearly having longer term data is advantageous, as you've alluded to, the regulatory expectation is that phase three studies will be run over 52 weeks. So ultimately decisions about efficacy will be made at the 52 week time point. So um, where we have more than 12 week data, uh, I think it can only build confidence further that the signal is sustained. Um, and as you've seen from the shape of the curve with blocks of coverage, um, perhaps the advantage of having run the study, uh, a good distance beyond 12 weeks is that we've seemingly begun to see a cumulative benefit. So, you know, when I'm talking to companies about study design, I tell them that I think 12 weeks is sort of the bare minimum and it is enough. But if we can go further, then it can only build confidence, um, that there is durability of treatment effect.

Unknown 1
46:16 - 46:19

Okay. Thank you very much. Appreciate it.

Operator
46:25 - 46:32

The next question comes from Cecilia Hernandez from Van Kempen. Please go ahead.

Unknown 2
46:32 - 46:44

Thank you. Congrats on the results and thank you for taking my question. Also a question for Toby. With all these developments in the IPF space, what about Buloxibutid's profile excites you the most? Thank you.

Prof. Toby Maher
46:47 - 48:20

Um, I think two things, uh, I obviously, you know, one always has to caveat one's enthusiasm about the improvement in FVC that we see over the 36 weeks, given that it's an open label study. So I, you know, I don't want to sound like I'm getting too carried away. But on the other hand, um, the, the lung function trajectory that we are seeing is completely different to anything that we've seen before. So to have a treatment, you know, let's say that plays out in the phase to be, um, to have a treatment that genuinely improves lung function over time, uh, would really be a paradigm shift in this disease area. So I think that's, that's reason for, uh, you know, cautious excitement. Um, and I think the other important factor is the tolerability profile, um, you know, our existing drugs and several of the drugs in development, um, are potentially very difficult for patients to tolerate. I'm with Nintedanib. We see when Nintedanib is used in community practice, about 50% of patients discontinue therapy at 12 months because of gastrointestinal side effects. So what we've seen with Buloxibutid, um, suggests to me that it should be a drug that is relatively easy for patients to take long term. So that combination of efficacy and good tolerability, uh, really makes this a very exciting program.

Unknown 2
48:24 - 48:25

Thank you.

Operator
48:29 - 48:35

The next question comes from Patrick Ling from DNB Markets. Please go ahead.

Unknown 3
48:37 - 49:03

Thank you guys. Uh. Two questions. Uh, actually one more for Ahmed. I think, first can you say anything about what you expect the Phase 2b trial will cost? And if the financial resources that you have on your balance sheet right now are sufficient for you to bring that trial to completion.

Ahmed Mousa
49:05 - 49:46

Yes, those were great questions. And thank you, Patrick, for joining. We currently have a cash runway that takes us into 2026, as we've guided publicly. So we really have a strong balance sheet to push forward in a significant way. And of course, it's been really great to also build the, um, uh, to build the, uh, uh, support with the deal with GNS Pharma, where we've licensed regional rights in Japan. Of course, that brought in upfront payments. It'll bring in milestone payments and also some cost sharing for both the nonclinical, like the CMC costs, a portion of those, as well as the late-stage clinical development costs as well.

Unknown 3
49:49 - 50:10

Okay. In the trial, you had several interim readouts. Will you have anything similar in this trial or will we just have to wait until the trial is completely finished before we get any sense of direction from the trial?

Unknown 4
50:11 - 50:13

Yes, absolutely. It's a great question.

Ahmed Mousa
50:13 - 50:50

For both regulatory reasons and because this will now be a placebo-controlled study, there are limitations around what can be done to ensure we have the right regulatory interactions with the FDA. Our hope and anticipation is that with a positive Phase 2b readout, we could engage with the FDA to facilitate having only one Phase 3 trial in order to get the drug approved. For that reason, among others, we will not have an effective interim analysis. There will be an interim analysis for futility built into the study. The.

Unknown 3
50:53 - 51:10

Okay. And then lastly, I mean, since these patients might be on placebo as well, how do you handle if the patients drop out? Because as Professor Maher said, I mean, most patients drop out within 12 months of treatment due to noncompliance.

Ahmed Mousa
51:11 - 52:05

Yes, that's a great question. So as part of our power calculation, we have assumed a particular dropout rate. And that is in line with what's been observed in prior clinical studies, including previous phase two and phase three studies. So, we've made a baseline assumption of what we expect for a typical study, the dropout rate to be; it's consistent with what, for example, the post-12 week or even a little bit more conservative than what the post-12 week dropout rate was in the Phase 2a AIR trial. And in addition to that, we'll be able to observe on a blinded basis the dropout or withdrawal rates. So if there's any kind of shift from the assumptions and a need to think about adjusting the powering, there is that opportunity built into the protocol as well, in case something unanticipated does occur.

Unknown 3
52:07 - 52:11

Okay. Great. Thank you, guys. Thanks.

Operator
52:19 - 52:27

There are no more questions from the phone conference, so I hand the conference back to the speakers for any written questions from the chat and comments.

Megan Richards
52:29 - 52:44

Excellent. Thank you for those great questions on the phone. Turning over to the chat, we do have a lot of great questions coming in. So first I want to start off with a question from Jeff Jones at Oppenheimer. Can you comment on the impact of outlier patients on these mean FVC results?

Ahmed Mousa
52:45 - 52:52

Yeah. I think, uh, Pirtle did a great job talking through that. But why don't you recap, you know, some of the discussion you did on that point?

Bertil Lindmark
52:52 - 53:41

Yeah, we saw 65% of patients sort of improving their lung function. And obviously when we look at the mean and median, the main improvement was 216 mL. And the median was, I think from memory, about 63. So this really shows that the majority of patients sort of improve their lung function. Obviously in a study like this, you will have patients improving and patients not improving because that's the nature of the disease. But as a cohort, we can say very clearly that when we cut the data materially into gender, geography, type of IPF, we think that the data is internally consistent and it's not driven by, by a single or a small number of outliers.

Megan Richards
53:47 - 54:01

Excellent. Thank you. Bertil. Uh, looking at the next couple of questions, we're actually getting a few similar ones from folks in the chat, so I'll consolidate them here. When do you expect the Phase 2b ASPIRE trial to start? And have you received any feedback from investigators?

Ahmed Mousa
54:03 - 55:34

Yeah, absolutely. So, um, we expect to again make the regulatory submissions to initiate the study, uh, next month. And then you would start screening and enrollment following kind of regulatory clearance in the months thereafter. So, we're really excited to kind of push forward. Uh, you know, Professor Maher talked a little bit about the reasons why, um, you know, people might be excited for this study and why, you know, it might kind of be a, you know, relative to the competitive landscape of IPF and that it's a rare disease, and kind of an efficient enrollee in that context. And we certainly hope that will be the case. We're getting good initial signals on that front. We had kind of a packed room for our investigator meeting at ATS 2024 with some of the Phase 2b ASPIRE trial investigators who were attending the conference. Uh, as I think I've mentioned, we have 97 clinical sites, so that means we've already kind of aligned with those sites that we would like to include them, and they would like to participate in the study. And at least for now, that'll be kind of the number of sites that we have. So, you know, now we're kind of generating a little bit of a waiting list or kind of a list of others that maybe we can think about expanding in the future if it is needed. But I would say that the early signals on enthusiasm are quite nice. And I think it is this, you know, first and foremost, having a safe and well-tolerated drug that's easy for patients to take, especially since we're going on top of the new standard of care. And then on top of that, having this promise of potential efficacy based on the Phase 2a AIR trial signal that's getting some of the investigators excited as well. So I think the initial signals there are quite good.

Unknown 5
55:38 - 55:39

Excellent.

Megan Richards
55:40 - 55:47

Uh, another question from the chat here. What is the reason behind the hair loss seen with Buloxibutid? And how does this impact the profile of the drug?

Ahmed Mousa
55:49 - 55:52

That's a good question. Maybe I'll hand that over to Bertil. Exactly.

Bertil Lindmark
55:52 - 56:43

Yeah. No. As I mentioned, this is seen in a minority of patients. And, um, we saw one patient, uh, stopping therapy because of the hair loss. Excuse me. The exact reason why we see it is not known. And we have started a program to look at the sort of the background, whether or not it's on target or off target. We think that it is manageable. I think it's mild and or moderate. Many still. Professor Maher, um, mentioned the sort of the population group that we're looking at here, sort of male, predominantly males, uh, aged 60 to 75, etc., probably can tolerate some of this hair loss, especially if we improve lung function. But it's, um, at this point in time, the jury's out on the exact mechanism.

Unknown 5
56:47 - 56:47

Excellent.

Megan Richards
56:47 - 56:57

It looks like we have time for about 1 or 2 more questions, so, um, I'll go with a provocative one. Why do you think that you will succeed where others may have failed?

Unknown 4
56:59 - 57:01

Uh, that's, uh, that's a great question.

Ahmed Mousa
57:01 - 58:11

I think, you know, some of the discussion, you know that I did at the top and the bottom really encapsulate that, you know, that you're going after a disease with an upstream mechanism of action that drives an endogenous tissue repair system, quite distinct, I think, from some of the other approaches that are downstream antagonistic and block collagen deposition, that you're also able to impact fibrosis in multiple ways, you know, reducing build-up and driving the breakdown, but also that you're able to have this impact on surfactant production, which is, you know, in a way, broadly being recognized as an important piece of the puzzle in IPF. So we think each of those pieces is important. I think the other thing that you might notice if you look at the literature in the IPF space is a lot of, uh, you know, kind of scientists and academics are focusing on these type two epithelial cells and the refunctionalization of these cells, you know we think is quite an exciting thing to do. And we think, you know, that drives a kind of broad range of beneficial effects. And I think, you know that those things give us hope that we can do something, you know, different based on this initial signal and the translational data that we have.

Unknown 5
58:16 - 58:16

Excellent.

Megan Richards
58:16 - 58:33

Well, it looks like that is all the time that we have today for this session. So thank you all for taking the time to join. I know we had a lot of great engagement in the chat, and we were not able to get to all of the questions, but we would love to follow up with you, so please feel free to reach out to us after this meeting. Thank you so much for attending and enjoy the rest of your day.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…